News
China’s 3SBio Soars on Granting Pfizer New Cancer Drug Rights in USD6 Billion Deal
3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF for cancer treatment, according to the agreement announced yesterday. The deal also includes an option for Pfizer to acquire commercialization rights in China.
The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...
Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...
Pfizer's reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics ... If those results are positive the partners have said they could file for approval in the ...
The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...
With the company’s Q1 2025 results on Tuesday, Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies ...
Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...
Pharmaceutical and biotechnology company Pfizer marks 70 years of dedication to its mission of advancing patient health in ...
Zacks Investment Research on MSN23h
Pfizer Buys Rights to PD-1 & VEGF Inhibitor From China BiotechPfizer PFE announced that it is in-licensing global development and commercialization rights, ex-China, to SSGJ-707, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback